Initiatives to stimulate innovation, especially around drug research and development (R&D), have been the most impactful, in our view, says Invesco New York chief investment officer for developing markets equities and senior portfolio manager Justin Leverenz.
The result is a booming drug R&D ecosystem including quality biotechs and their R&D outsourcing partner companies.
We expect reforms to provide tremendous industry tailwinds for the next decade and, as long-term investors in this space, we are excited about the new opportunities that are being created.
The value of investments and any income will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.
This article is for professional clients only and is not for consumer use.
Where individuals or the business have expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice.
Issued by Invesco Asset Management Limited, Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH, UK. Authorised and regulated by the Financial Conduct Authority.